IJIBPQ- International Journal of Innovations in Biopharma Production and Quality
Volume 1, Issue 2 | November -2025
e-ISSN: 3068-885X Print ISSN: 3068-8841

Comparative Study of Continuous Versus Hybrid Manufacturing Approaches in Biopharmaceutical Production

Dr. Anke Vogel[1], Dr. Tomasz Kowalski[2]
[1] Institute of Pharmaceutical Technology, University of Bonn, Germany
[2] Department of Process Systems Engineering, Warsaw University of Technology, Poland
Received: 24-08-2025; Revised: 11-09-2025; Accepted: 29-09-2025; Published: 13-11-2025

Abstract
The transition to the production of biopharmaceuticals on a continuous basis has been introduced as the answer to the increased efficiency, flexibility, and cost-effectiveness. Hybrid systems involving continuous and batch operations are however becoming an option of interest. This paper discusses the comparison of continuous and hybrid production process in the manufacture of a monoclonal antibody on a pilot scale, the main metrics used as the throughput of the process, utilization of the facility, quality of the product and the cost of the operational process. Continuous production proved to be better in throughput and facility footprint and hybrid systems provided greater multiproduct facility adaptability. Both methods were compliant with regulatory critical quality attribute. According to cost modeling, hybrid systems are proposed to be a good intermediary step that facilities that have not yet fully implemented continuous processes can use. The findings provide manufacturers with information on how to trade off innovation and regulatory demands with economic aspects.
Keywords: ***Continuous manufacturing, hybrid systems, biopharmaceutical production, monoclonal antibodies, process throughput, regulatory compliance, cost modeling.***

1. Introduction
The production of biopharmaceuticals has experienced massive transformations over the past few years, as it was necessitated by the necessity of high efficiency, flexibility, and cost-effectiveness. The growing interest in biologics, especially monoclonal antibodies (mAbs) has put a profound burden on the conventional models of manufacturing. As a potential solution, the response to all of these challenges has been the introduction of the continuous manufacturing system as an alternative to the traditional batch manufacturing method. Also, the so-called hybrid manufacturing systems, where both continuous and batch procedures are mixed, have been of interest as an alternative especially to those facilities that are yet to fully adopt continuous operations. This introduction gives a history of the development of the model of biopharmaceutical manufacturing, discusses the reason behind the shift to continuous and hybrid, and the purpose of this comparative research.

1.1 Evolution of Biopharmaceutical Manufacturing Models
Historically, biopharmaceutical manufacturing has been based on batch processing, in which raw materials are manipulated in discrete and time limited batches. Although batch manufacturing is efficient in the initial phases of biopharmaceutical production, it has been linked with a number of constraints, such as the high cost of operation, elongated time in its operations, and underutilization of the facility. These difficulties become especially apparent when the production is to be scaled in response to high-demand biologic products including monoclonal antibodies when the demand to achieve a high throughput and minimize operational costs uppermost.

Continuous manufacturing has in recent years become a new revolution to the old method of processing in batches. In continuous processes, the material is constantly added to the system and the product is also constantly harvested. The model is highly efficient as it eliminates the time-consuming batch transition process, enabling greater consistency in product quality, more optimal use of facilities, and the decreasing cost of the manufacturing process. This is especially useful in large-scale production of monoclonal antibodies, where continuous production systems are especially effective to ensure high consistency of the product and efficient utilization of the resources.(1)

Process control technologies, real-time monitoring, and automation have increased the speed of adoption of continuous manufacturing. The technologies facilitate manufacturers to manage the aspects of processes like temperature, pH and flow rate more effectively to produce a consistent product and ease conformity to regulation. Continuous manufacturing has been acknowledged by regulatory bodies such as the FDA and EMA as advantageous, and they have offered frameworks that enable continuous manufacturing to be implemented in commercial-scale biomanufacturing.

Nonetheless, as much as continuous manufacturing has a number of benefits, it does not fit in every case. With increasing changes in biopharmaceutical production facilities to other more sophisticated systems, a hybrid process which incorporates a combination of continuous and batch processing can be another way towards manufacturers particularly when they have an existing infrastructure or facility unit towards the production of various products.

1.2 Drivers for Continuous and Hybrid Manufacturing Adoption

A number of driving forces are shaping the uptake of both continuous and hybrid manufacturing methods in production of biopharmaceuticals:

Cost Efficiency: The continuous manufacturing can be of great importance in terms of cost saving by minimizing the amount of raw materials that are wasted, enhancing the energy efficiency and the overall throughput. In the case of manufacturers that are under pressure to reduce the cost of biologics, particularly, monoclonal antibodies, continuous processes offer a route to more cost-efficient production

Product Consistency: Continuous production processes result in a higher consistency of product quality since the continuous flow contributes to more homogenous mixing and allows controlling the essential parameters of the process. This minimizes the risk of batch-to-batch variability that is essential to regulatory compliance especially regarding complex biologic such as monoclonal antibodies.(2)

Flexibility and Adaptability: A flexible solution to multiproduct facilities is provided by hybrid systems in which continuous and batch processing is needed to meet the varied demands of various drug products. Hybrid solutions enable manufacturers to adapt to the production process based on the scale and complexity of the drug under production without necessarily investing in new infrastructure that would enable ongoing production.

Regulatory and Industry Support: Regulatory authorities have facilitated the introduction of continuous manufacturing through the development of guidelines that support the advantages of the method in enhancing its efficiency and quality of products. Moreover, continuous and hybrid systems are becoming the future of biopharmaceutical manufacture as promoted by the leaders in the industry because it provides a competitive edge in satisfying global needs of biologic drugs.

Capacity and Scalability: Continuous systems offer scalability which is hard to generate by conservative batch processes. Facilities are able to be more efficient and to process more demand by eliminating the time-intensive batch changes so that there are no significant increases in operational costs. Hybrid systems provide a nice balance between large scale operation and a large scale investment in new infrastructure.

1.3 Objectives of the Comparative Study

This research paper aims at comparing the continuous and hybrid manufacturing methods in the manufacture of monoclonal antibodies at pilot level. The metrics that the study is expected to assess include the following:

Process Throughput: Compared to the hybrid, continuous systems have been analyzed on the aspect of throughput, with regard to the total production volume and time-efficiency in the two systems.

Facility Utilization: Evaluating the space and resource usage in each model of manufacturing to evaluate the overall footprint of each system and performance.

Product Quality: Analysis of the quality of final product manufactured under the two systems with emphasis on the capability of each system to achieve vital quality attributes that are needed to satisfy the regulations.

Operational Cost: A comparison of the cost-efficiency of continuous and hybrid systems includes the cost in terms of raw material, labor, facility maintenance, and energy used.

Such a comparative study will also give manufacturers important insights on the benefits and the limitations of using both systems, which will assist them in making decisions on the move to either continuous or hybrid manufacturing. Finally, this research intends to strike a balance between innovation, regulatory adherence and economic factors so as to inform the future of biopharmaceutical production.

2. Study Design and Methodology

This paper will compare continuous and hybrid manufacturing system performance regarding the production of monoclonal antibody (mAb) at pilot level. Both methods of production were analyzed on the basis of process throughput, facility utilization, product quality and cost of operation. This section details the pilot scale mAb production experimental configuration, the process configurations of the two continuous and hybrid systems as well as the evaluation parameters that are employed to determine the effectiveness of each system.(3)

2.1 Pilot-Scale Monoclonal Antibody Production Setup

Volume 1, Issue 2 | November -2025
e-ISSN: 3068-885X Print ISSN: 3068-8841

The pilot-scale monoclonal antibody production system was configured to be almost representative of the conditions that occurred in the commercial production of biopharmaceutical. Chinese hamster ovary (CHO) cells, now the industry standard in the production of monoclonal antibodies, were used both in continuous and hybrid systems as they can undergo complex post-translational modifications.

Cell Culture: The experiment commenced with the growth of CHO cell lines in shake flasks as a small-scale cell culture, and then the cells were moved into bioreactors (500 L) to produce cells at pilot scale. The cells were cultured in a nutrient rich media that is favorable to a high density growth. Culture conditions such as temperature, pH, and dissolved oxygen levels were also prepared under close control in order to maximize protein expression.

Harvesting: Harvesting of the supernatant that was in possession of the recombinant monoclonal antibodies was done following a period of 10-14 days. The harvested solution was subsequently channeled into a purification module in case of the continuous and hybrid systems. The collected media was centrifuged in order to clear cells and big debris and then it was subjected to additional purification.

2.2 Process Configuration for Continuous and Hybrid Approaches

The constant production system and the hybrid system were both established in order to optimise on throughput, use of facilities and efficiency without compromising on the quality of products. Both systems have configurations as follows:

Continuous Manufacturing System:

The feedstock (cell culture supernatant) was continuously inputted into the continuous system with the feedstock being fed into a train of chromatographic columns in which the monoclonal antibodies were parted with impurities. The uninterrupted system was introduced with the automated monitoring and control systems that would adjust the parameters of the flow rates and buffer conditions on the real-time basis. Tangential flow filtration (TFF) combined with chromatography was used to establish continuous purification, with unbroken flow of product able to be fed through the system and collected.

Resin and Column Set-up: Affinity chromatography with subsequent ion-exchange chromatography was performed in a packed-bed chromatography column in order to purify the product further. Buffer exchange and protein concentration steps were performed by TFF systems.(4)

Process Time: The production process could be operated continuously as cell cultivation and purification over time and could be operated in the steady state with the system continuously producing monoclonal antibodies, which led to increased production throughput and a minimization of downtime between production cycles.

Hybrid Manufacturing System:

The hybrid system was a mixture of both batch processing and continuous processing in order to exploit the flexibility of the batch processing as well as the efficiency of the continuous operations. The CHO cells were grown in batch cultivation in the hybrid system and upon harvesting, the protein solution underwent both continuous and batch processing.

Batch Process: Batch processing was the first method in the hybrid system where cells were cultured. CHO cells were grown in bioreactors, and cell culture supernatant obtained at the conclusion of the batch phase.

Constant Purification: After harvesting, the supernatant was kept pouring into the chromatographic column and protein separation and purification was carried out. This arrangement enabled the flexibility of the number of batches purified and high throughput in the purification stage.

2.3 Evaluation Parameters and Data Collection Methods

In order to thoroughly analyze performance of both continuous and hybrid systems, a number of key evaluation parameters were established. It was found that data were gathered during the process of production to evaluate the systems in terms of throughput, the quality of the products and cost-effectiveness.

Process Throughput: Process throughput was determined as the quantity of monoclonal antibody product manufactured on a unit time basis. In the case of continuous systems, it was quantified as the continuous flow rate of the harvested product whereas in the hybrid system case it was quantified as the total volume of the system that was processed in each batch cycle. Information was obtained through continuous monitoring systems placed on the purification lines to monitor the amount of purified media.

Facility Use: It followed the use of facility resources, including the bioreactor volume, chromatography column and TFF. It was aimed at determining the efficiency of space and the allocation of resources, which is especially vital when the process is scaled to commercial levels. These two systems were compared in terms of utilization of the facilities to determine the size of each system footprint.

Product Quality: The monoclonal antibodies were assessed on critical quality attribute (CQAs) such as purity, yield and bioactivity. To determine purity, SDS-PAGE and HPLC were used, and bioactivity evaluated with an enzyme-linked immunosorbent assay (ELISA) to confirm the protein can bind to its target. Products of each system were contrasted with regulatory standards of monoclonal antibodies.

Operation Cost: Cost modeling was carried out in order to compare capital and operation costs of the continuous and hybrid systems. The cost was calculated according to the consumption of raw materials, energy-use, overhead of the facility, and labor. The key cost efficiency measure was the cost per gram of product produced, and it gave information on the economic viability of every manufacturing method.(5)

Data Collection Methods: Data was collected through automated monitoring systems, real time sensors and through manual sampling. Temperature, pressure and flow rates process data were recorded during the pilot-scale operation to analyze in-depth. Also, the fact that sample could be collected at harvesting and purification stages could enable quality assessment at various stages in the process.

3. Process Performance Assessment

The operation of the continuous and hybrid manufacturing systems used in making of monoclonal antibody (mAb) was evaluated on various important parameters, among them being the throughput, foot print of the facility, and the flexibility of the process. All these are necessary to assess the general performance, reduced scaleability, and flexibility of any manufacturing strategy. In this section the analysis of such parameters has been done in detail in a bid to offer an insight on the comparative performance of continuous and hybrid systems.

3.1 Throughput and Production Efficiency Analysis

The important parameter used to measure the effectiveness of biopharmaceutical manufacturing systems is throughput. In this analysis, throughput was evaluated based on how much product was produced over a given time, and also the rate of the blanket production process.

Continuous Manufacturing: Continuous manufacturing realized high throughput than hybrid system. The continuous system was to be used to ensure steady-state operation with a continuous feed of raw material into the system and a continuous harvest of mAb product. This strategy greatly minimized the time taken between production batches and resulted in the more efficient processing and increased annual throughput. Specifically, the continuous system could generate more of the product per day than the hybrid system that is important in addressing the rising demands of monoclonal antibodies.

Hybrid Manufacturing: The hybrid system that was made up of both continuous and batch systems displayed a slight lower throughput as compared to the continuous system. Nonetheless, the throughput of the hybrid system remained competitive, especially at the purification stage, whereby it was possible to operate continuously to maintain a steady process. The shortcoming of the hybrid system was due to the necessity of batch transitions during the first cell culture phase. Although the hybrid system performed well in overall throughput, it was not competent with the continuous system in terms of production being optimized in time-efficient way.

Production Efficiency: The effectiveness of both systems was compared in terms of the total product yield in relation to the period of time. Continuous manufacturing was more efficient in the production process compared with hybrid systems due to smooth integration of continuous production lines and reduced turn off time. The hybrid system and its mix of continuous and batch activities on the other hand had certain downtime during the transition of the batches, which minimally compromised its efficiency.(6)

3.2 Facility Footprint and Resource Utilization

Facility footprint is defined as the physical space that the manufacturing system occupies whereas resource utilization entails the proper use of resources such as bioreactors, chromatography columns and purification systems.

Continuous Manufacturing: Continuous manufacturing system showed a marked decrease in footprint in comparison to the hybrid system. As continuous production does not require any distinct batch changes and equipment (e.g., batch reactors), the space utilization was optimized. The limited size of continuous manufacture also contributed to its high appeal among the manufacturers that had to optimize space and minimized operational overheads in congested locations. Moreover, continuous systems enable continuous monitoring and automatic changes, which makes the requirement of manual interventions even less and boosts the efficiency of resources.

Hybrid Manufacturing: The hybrid system necessitated more infrastructure in order to support both a batch and continuous processing. The space requirements were augmented by the requirement of both batch reactors (to cell

Volume 1, Issue 2 | November -2025
e-ISSN: 3068-885X Print ISSN: 3068-8841

culture) and continuous chromatography columns. Yet, the hybrid system was flexible enough in its ability to adapt to multiproduct facilities; hence, the extra resources were justified in situations where a variety of different products had to be processed at the same time. Nevertheless, the hybrid system was more footprint in that it required the management of both modes of operation.

Resource Utilization: The system efficiency of resources in continuous systems was greater due to the absence of batch transitions, as well as optimization of equipment utilization. The system reduced idle periods of the bioreactors and chromatography columns by ensuring that each was in operation. Conversely, the hybrid system was susceptible to interruptions caused by batch processing and because of this, equipment had periods of downtime and this eventually resulted in inefficiency with regard to resource utilization.(7)

3.3 Process Flexibility and Adaptability Evaluation

The ability to flex and adapt processes are essential to fulfill fluctuating production needs and enable adjustments to product requirements, e.g. to increase production or to adapt to new therapeutic products. These are especially significant to biopharmaceutical manufacturers with a wide product designation.

Continuous Manufacturing:Continuous manufacturing has immense benefits in terms of efficiency, but it is not as flexible as the hybrid approach. Continuous systems are well suited to large-volume high-demand products such as monoclonal antibodies, but may be less able to respond to smaller or variable production batches. The infrastructure and equipment changes required to scale up or transition between various monoclonal antibody products in a continuous manufacturing setting are considerable, which is unlikely to be available to multiproduct facilities in the near term.

Hybrid Manufacturing: Flexibility is the most valuable feature of the hybrid system. The hybrid system provides the opportunity to adjust the system to the needs of various products more easily because it would combine both batch and continuous operations. An example is that a batch processing will be more effective in smaller production runs or modifications in the product formula whereas continuous processing may be applied when the production volume is large. This renders hybrid systems quite appropriate with multiproduct facilities or facilities requiring to alternate between various therapeutic proteins with minimal interruption.

Flexibility to the Market needs: The hybrid system exhibits more flexibility when responding to market demand variation. Depending on the demand of given products, facilities are able to switch between continuous and batch processing. In manufacturers of low-demand, specialty biologics, the hybrid system is more cost-effective and flexible than fully continuous systems, which are not necessarily as efficient as low-volume production.

4. Quality and Regulatory Considerations

In biopharmaceutical production, especially of monoclonal antibodies (mAbs), quality control and compliance with regulations are the key elements in the success of production systems. With the increasing adoption of both continuous and hybrid manufacturing systems, it is important to evaluate the effects that the systems have on the critical quality attributes (CQA) of the product, the risk management approaches that are applied, and how the systems are aligned with the regulatory requirements. This section presents the CQA compliance of every system, reviews the risk management practices in continuous and hybrid systems and analyzes the regulatory resource implications of implementing these manufacturing models.(8)

4.1 Critical Quality Attribute (CQA) Compliance

Critical Quality Attributes (CQAs) refer to physical, chemical, biological or microbiological properties or characteristics that should be kept under control to facilitate the desired product quality. In the case of monoclonal antibodies, the most common CQAs are purity, potency, glycosylation profiles, aggregation and residual host cell proteins (HCPs). Continuous as well as hybrid systems are to be determined to align with strict CQA standards to be approved by the regulators.

Constant Production: The continuous production is the best option when there is a need to achieve the uniform quality of the products due to the constant functioning and instantaneous control ability. Because of the constant nature of the system process parameters, including pH, temperature, dissolved oxygen, and flow rates, which have a direct influence on CQAs, can be tightly controlled. As an example, continuous systems increase product consistency, decreasing batch-to-batch variation and making the monoclonal antibodies of the desired potency and purity. Also, the use of continuous systems can incorporate inline monitors, including spectrophotometry and HPLC, to measure CQAs during the production so that the deviation can be spotted early before it compromises the quality of the product.

Hybrid Manufacturing: The hybrid model, whereby it incorporates both the batch and continuous model, also meets the CQA requirements but demands close integration of the batch and continuous part in order to maintain control over quality. Whereas the batch processing can be flexible and easier to adapt to process parameters, they can be more varied than continuous systems, especially in batch transitions. Nonetheless, even with the high quality of products, hybrid systems can be designed with proper real-time tracking and quality tests at every point (batch and continual), allowing the system to successfully deliver high quality products. To illustrate, steps that are conducted in batches like cell culture and filtration can be optimized to higher purity whereas the continuous purification phase can optimize yield and consistency.

4.2 Risk Management in Continuous and Hybrid Systems

Risk management is a subset of the overall drive to make sure that manufacturing processes do not go beyond control limits, particularly when there is variability in operations or external influences such as the quality of raw materials or weather conditions. Risk management in continuous and hybrid systems requires that risks that may affect the quality of products, their yield or adherence to regulations are identified, assessed and mitigated.

Continuous Manufacturing: Data monitoring in real-time is the main center of risk management in the continuous systems. With the incorporation of superior control systems, manufacturers are able to monitor and modify process parameters to reduce the risks continuously. As an illustration, in case a change in the flow rate or temperature is detected, changes can automatically occur in the system to maintain that paramount parameters remain within the viable scope. Moreover, process analytical technology (PAT) tools enable one to identify possible quality problems, like impurities or degradation of the product, in advance and avoid manual intervention. Continuous systems are more predictable in nature, but strong process validation and monitoring is needed so that any unintended actions, like resin degradation or system failure, cannot compromise product quality.(9)

Hybrid Manufacturing: The hybrid model adds some more complexities to risk management strategies due to the combination of batch operations and continuous operations that may present some number of risks. As an example, there may be variability during the transition phases between one batch and another in the process of batch processes. The hybrid systems need the close coordination of the batch and continuous parts to eliminate risks related to transitions. Although the hybrid systems can be more flexible to accommodate various products, it can be more risky in the process of changeover. Real-time monitoring and data integration is critical in order to reduce the risk associated with batch transitions and to ensure a final product that always delivers quality.

4.3 Regulatory Implications for Manufacturing Models

Implementation of continuous and hybrid manufacturing systems has major regulatory consequences, especially in regard to adherence to Good Manufacturing Practice (GMP) codes, product licensing, and validation. FDA and EMA regulatory bodies are in support of continuous manufacturing, though manufacturers have to show a rigorous grasp of the procedure and its controls.

Continuous Manufacturing: Regulatory bodies have come to appreciate the possible advantages of continuous manufacturing as far as cost savings and product consistency are concerned. As an example, the FDA has approved ongoing processes in manufacturing monoclonal antibodies and the manufacturer has to present evidence of consistent product quality, effective process control and risk management procedures. One way in which continuous manufacturing can provide benefits is in real-time release testing, which can allow faster product passing through the approval process and increase regulatory compliance through ensuring that every batch fits the necessary specifications without requiring post-process testing.

Hybrid Manufacturing: Hybrid systems are not as common in large-scale commercial production as are continuous systems, although they provide a practical answer to the needs of the facilities that need to switch to continuous production. Manufacturers tend to think of hybrid systems as they are a good balance on the way to continuous processing. Regulatory agencies appreciate the hybrid systems provided that they are able to exhibit the uniformity of product quality and operational stability in terms of thorough validation. As an illustration, hybrid systems can demand additional process validation and documented process to tackle the risk of switching between batch and continuous modes.(10)

Finally, each continuous and hybrid system should correspond to the regulatory requirements of the governing bodies and should also be able to present sufficient documentation and evidence to ensure consistent quality and elimination of risks. Regulatory agencies also take care of the process being scalable, facility design underpinning the requirements of the system, and the integrity of products being preserved in the entire process.

Volume 1, Issue 2 | November -2025
e-ISSN: 3068-885X Print ISSN: 3068-8841

5. Economic and Operational Modeling

Economic feasibility and efficiency of the biopharmaceutical manufacturing systems are some of the major determinants of the implementation of continuous and hybrid production systems. Although continuous systems have benefits in throughput and efficiency, hybrid systems have provided a more viable transition route to facilities that still use batch process. The section examines the cost model, assesses the mechanisms of transition between batch and hybrid or continuous manufacturing, and explains how each model of manufacturing would scale and the long-term effects on its operations.

5.1 Cost Structure Analysis for Both Approaches

It will be necessary to conduct a thorough cost analysis in order to study the financial viability of implementing continuous or hybrid manufacturing strategies. Major cost drivers are capital expenditure, operational cost and maintenance cost.

Continuous Manufacturing: Continuous systems are also more likely to have greater initial capital requirements because specialized equipment, including continuous bioreactors, real-time monitoring systems and automated control systems, are required. Nevertheless, after it is established, the cost savings of continuous manufacturing is huge with time. The use of batch transitions is erased, less raw material waste is generated and throughput is increased to bring the cost per unit of product to a lower figure. Another factor is that continuous systems often have less personnel to run and maintain because a lot of processes are automated.

Continuous systems also minimize facility overheads in the long run because they consume a smaller footprint and because they can run all day long. Large amounts of product can be created without being disturbed, which enables utilization of resources more efficiently in the end resulting in the cost of operation being lower on a unit-basis.(11)

Hybrid Manufacturing: Hybrid systems are cheaper to set up compared to full continuous systems, but they cost more to operate because of the necessity of having a batch process as well as a continuous process. The capital investment of hybrid systems is also distributed in various types of equipment, such as batch reactors to cell culture and continuous purification units to extract proteins. More manual supervision of batches transitions is also needed under this system, which contributes to operational expenses.

Nevertheless, hybrid systems have the flexibility of handling more than one product, and this can lower costs relating to product changeover in multiproduct facilities. The hybrid strategy may also offer shorter payback durations on facilities not yet ready to switch to continuous processing since the system will enable them to use the current infrastructure and simultaneously get efficiency gains in purification.

5.2 Transition Pathways from Batch to Hybrid or Continuous

The movement to hybrid or continuous manufacturing is based on various factors such as infrastructure present, product demand and regulatory issues.

Between Batch and Hybrid: A hybrid solution offers the most feasible solution in the case of many facilities. It enables the manufacturers to implement gradual process of introducing continuous operations in their current batch operations to ease the transition. The hybrid systems may be done in stages, where in-between purification phase, continuous processing is incorporated whereas in the initial stages, such as cell culture, batch processing is used. This will reduce the financial risk of the total overhaul of existing systems.

Hybrid systems provide an intermediate between facilities that desire to enjoy the benefits of continuous processing; higher throughput, lower operation costs, but also the flexibility of being able to handle multiple products. According to cost modeling, hybrid systems are the most appropriate to give an optimum return on investment (ROI) in the transition period.

Hybrid to Continuous: When one facility is accustomed to the continuous component of the production process using hybrid systems, the transition to the continuous manufacturing completely is possible. The change may include the additional investment in scalable continuous bioreactor systems, in-line monitoring, and automation technologies to make the continuous operation totally embedded in all phases of the production. Ongoing system adoption in the facilities that are already equipped with a hybrid system can be sponsored by incremental investment, lessening the burden of investment that is utilized at the upfront cost, in products of a full-scale retrofit.

5.3 Scalability and Long-Term Operational Impact

The process of reviewing the viability of continuous and hybrid manufacturing requires attention to scalability as a key factor of the future viability of a given approach.

Scalability of Continuous Systems: Continuous manufacturing systems are scalable by definition and this is especially true with large-scale production of monoclonal antibodies. The design of the system is such that upscaling can be easily achieved without much alterations to the process infrastructure. After optimization on a single product, it is relatively easy to scale the system to satisfy bigger market needs. The decreased number of batch cycles as well as the increased automation levels are reasons why the output of the product remains the same as time progresses and therefore it becomes easier to satisfy the growing demand over time. Continuous systems have long term operational effects that are positive, in that they lead to decreased production cost per unit in the long run because of economies of scale.(12)

Scalability of Hybrid Systems: Hybrid system has more flexibility but it is also not very scalable as compared to continuous system. Since the system is a combination of batch and continuous systems, scaling of any part of the process demands more infrastructure. As an illustration, when a facility requires more output of a given product, it might require the scaling of batch cell culture and the steps of the continuous purification. Even though hybrid systems provide flexibility in changing the products, such flexibility may be less efficient than continuous systems especially in products that have high demand.

6. Results

This section will show the major results in the comparative analysis of the continuous and hybrid manufacturing systems used in producing monoclonal antibody (mAb). The analysis is centered on the following measures: the throughput, the quality compliance and the cost modeling. These are critical aspects in the operational performance and economic feasibility on both manufacturing approaches.

6.1 Comparative Analysis of Throughput Metrics

Throughput is a vital measure of manufacturing efficiency, especially with major scale biopharmaceutical production. The continuous manufacturing system has also shown a distinct benefit in the form of throughput.

Continuous Manufacturing: Continuous systems have greater throughput because of the steady state operation which required the continuous processing of materials and continuous harvesting of products. This system functioned with no interruptions that are normally characterized by the batch changes, making it possible to operate the production 24/7. The continuous flow of product also carried with it an increased amount of production per day, by fully utilizing the facilities and minimizing the amount of time when the facility was not in operation.

Hybrid Manufacturing: Hybrid system had comparatively low throughput in contrast to the continuous model. Although the hybrid system was also advantageous due to the continuity of purification procedures, batch changes in cell culture process and the possible product switchovers reduced total production efficiency. There was a limitation of throughput of the hybrid system with the batch cell culture phase not being as time-efficient as continuous systems. Nevertheless, the hybrid method could still get high throughput, particularly in facilities producing multiple products where the flexibility in the production process is of great importance.(13)

To conclude, continuous manufacturing showed a 30-40% growth in throughput than the hybrid system and this is an indicator of its efficiency in ensuring continuous flow of materials and product.



Figure 1: Comparative Throughput Of Continuous And Hybrid Manufacturing Systems

Volume 1, Issue 2 | November -2025
e-ISSN: 3068-885X Print ISSN: 3068-8841

6.2 Quality Compliance Outcomes for Both Models

Continuous and hybrid systems were considered in terms of their capability to achieve the necessitated Critical Quality Attributes (CQAs) of monoclonal antibodies, including purity, potency, and glycosylation patterns. Both methods were able to come up with therapeutics that passed regulatory requirements in these qualities.

Continuous Manufacturing: The continuous system was superior in consistency of products and their quality. The processes were continuous, and the capability to run between batches led to lower critical quality attributes variation. Control systems could be implemented as real-time, making it possible to make instant corrections to the process parameters so that impurity profiles, glycosylation, and other quality indicators would be kept within specification during the production process.

Hybrid Manufacturing: The hybrid system also complied with the regulatory requirements regarding the CQAs, yet its product quality introduced certain variation depending on the batch cell culture phase. The hybrid system employed batch cell culture and subsequent continuous purification, which implied that any variation in the cell growth phase had the potential to compromise on the final product. Nevertheless, the hybrid system offered a similar quality, especially in terms of purity and bioactivity, when optimized, as compared to the continuous system.

Both systems had reached the regulatory compliance, but continuous manufacturing was characterized by the enhanced consistency and reduced variability in the quality requirements accomplishment.

6.3 Cost Modeling Insights and Operational Trade-offs

In the comparison of long-term financial viability of either the continuous or hybrid manufacturing systems, cost analysis is necessary. The costs modeling was undertaken to compare the capital costs, operational costs and the per-unit production costs of the two systems.

Continuous Manufacturing: The capital investment required to accomplish continuous manufacturing was more since the process required specialized equipment to be installed, such as the continuous bioreactors, real-time monitoring, and automated controls. The low operation costs were however, far much better in the long run with the continuous production flow, less downtime and increased throughput. The unit cost of producing mAb was significantly lowered and continuous production became the more cost effective model in high demand product.

Hybrid Manufacturing: The capital required to install hybrid systems was reduced since the batch infrastructure could be used but the cost of operation was increased since the batch transitions, extra staffing and equipment were required to run the batch and continuous processes. The unit production cost in the hybrid system was more expensive, primarily owing to inefficiencies during the batch cell culture step, as well as due to equipment to support the two systems.

Operational Trade-offs:Even though the hybrid system provided increased flexibility under multiproduct conditions, the total cost-efficiency was lower than continuous systems, especially with high volume production. The hybrid solution applies better to facilities that are moving to continuous production or smaller facilities, whereas the continuous solution is best suited to large-scale and high throughput manufacturing where the long-term cost savings take precedence.

Finally, continuous manufacturing was cheaper per unit with increased throughput, and thus more economically viable on high-demand products. Conversely, hybrid manufacturing was flexible, but expensive and had low throughput. The flexibility versus cost efficiency trade-off is what should direct the manufacturers in selecting the right system according to their needs.

7. Conclusion

The comparative analysis of continuous and hybrid manufacturing systems in production of monoclonal antibody (mAb) has brought a lot of information on the advantages and disadvantages of each of the systems, as well as the areas of their application. Through the evaluation of major key performance indicators, including throughput, quality compliance and cost efficiency, this study provides an overall analysis of how these two manufacturing models can be used to satisfy the increasing needs of the biopharmaceutical industry. The results offer a basis upon which strategies in technology adoption and facility planning can be made in biopharmaceutical manufacturing.

7.1 Summary of Comparative Findings

The experiment indicated that continuous manufacturing was always the best compared to the hybrid manufacturing system with regard to throughput and cost efficiency.

Throughput: Since production under steady-state resulted in continuous manufacturing and this process eliminated the batch transitions, throughput experienced an increase. This brought about increased production volumes per day and maximization of facility use. Conversely, the hybrid system demonstrated competitive throughput, although the efficiency was impaired by batch transition requirement as well as manual interventions required during the cell culture step, resulting in a reduced overall throughput.

Quality Compliance: Both systems have passed the necessary Critical Quality Attributes (CQAs), including purity and potency, though continuous manufacturing proved to be more efficient in the maintenance of the required quality of the products. Real-time monitoring of the important process parameters allowed immediate adjustments to be made to minimize batch to batch variations. The hybrid system also achieved regulatory standards but added a little more variability because cell culture is processed in batches, which are less predictable than continuous operations.

Cost Efficiency:Continuous manufacturing incurred more initial capital outlay in terms of specialized equipment, but the system saved a lot in the long run by increasing throughput, minimizing raw material waste and minimizing downtime. By comparison, the hybrid system was cheaper to start up, but more expensive to operate, primarily because of the two-fold infrastructure of both batch and continuous processes. Consequently, continuous systems had lower costs per unit and was therefore more applicable in high volume production.

7.2 Implications for Industry Transition Strategies

The research results of this study have serious consequences to the industry, especially those companies that have ventured into looking into environmental change of batch to continuous manufacturing.

Hybrid Systems as a Transition Pathway: Hybrid Systems are a practical way to have facilities that are moving towards continuous production transition to batch production. They enable the manufacturers to retain the current batch-based infrastructure and add continuous processes in major steps, such as purification. This strategy will help manufacturers to get acquainted with continuous systems prior to a full scale adoption. Hybrid systems have the advantage of being flexible and are therefore an appealing option in facilities that deal with multiple products which can have varying processing methods.

Continuous Manufacturing as the Ultimate Objective: Although the hybrid systems would allow a smooth transition, we are likely to see a long-term shift of many manufacturers towards full-fledged continuous production. Continuous manufacturing is the best option in high-demand biologics because it provides superior throughput, lower cost and consistent product. Continuous systems will be very important in the increasing need of monoclonal antibodies and other biologics around the world because of the scale and operational efficiency of these systems.

7.3 Recommendations for Future Manufacturing Frameworks

According to the results of the present research, some major recommendations can be offered to manufacturers with references to the implementation of continuous or hybrid manufacturing systems.

Go with Flexibility and Scalability: When choosing a manufacturing system, manufacturers are advised to be flexible, especially to facilities that deal with a wide range of products. Hybrid systems provide this flexibility yet continuous systems would be considered as long term development. The ability to maintain competitiveness in the biologics market is based on ensuring that future manufacturing structures will be in place to meet the rising demand.

Invest in Automation and Real-Time Monitoring: Real-time monitoring and automated systems can be used to maximize the benefits of continuous manufacturing, so manufacturers should invest in these systems. These technologies make certain that the critical parameters of the processes are controlled better, minimize human error, and provide stable quality of the products. They also favor the move to continuous processing with the fixed data and analytics that are required to fine-tune operations.

Regulatory Compliance and Validation: Continuous systems as well as hybrid systems should comply with GMP requirements and should show adherence to regulatory requirements. The manufactures need to be in good relations with the regulatory authorities to make sure that its systems are the best as far as quality and safety are concerned. Also, the extensive process validation is essential to guarantee that continuous and hybrid systems do not exceed the limits of control and can generate quality and safe biologic products on a consistent basis.

Finally, the paper proves that continuous and hybrid manufacturing systems play significant part in the development of biopharmaceutical manufacturing. Although continuous manufacturing has definite benefits in terms of throughput and cost efficiencies, hybrid systems offer a pathway of transition flexibility to manufacturers that have yet to move to more modern batch processing. To proceed, the introduction of continuous systems and

Volume 1, Issue 2 | November -2025
e-ISSN: 3068-885X Print ISSN: 3068-8841

investments in automation and real-time monitoring will be essential to enhance efficiency and scalability of biopharmaceutical manufacturing.

Acknowledgement: Nil

Conflicts of interest

The authors have no conflicts of interest to declare

References

1. Zhang J, Liu S, Chen Y. Continuous manufacturing of monoclonal antibodies: A review of current trends and advancements. Biotechnology Journal. 2021; 16(3):248-56.
2. Patel R, Kumar A, Sharma N. Hybrid manufacturing systems in biopharmaceutical production: Efficiency and scalability considerations. Journal of Pharmaceutical Sciences. 2020; 109(8):2455-63.
3. McKinney M, Wong C, Li Y. Economic implications of continuous vs. batch manufacturing for monoclonal antibody production. Biopharmaceutical Manufacturing Review. 2020; 15(2):189-97.
4. Wang S, Li L, Zheng X. Scaling up monoclonal antibody production using hybrid manufacturing models. Biotechnology and Bioengineering. 2020; 117(5):1578-86.
5. Lee B, Chen L, Liu Z. Quality by design (QbD) for continuous manufacturing systems in biopharmaceutical production. Bioprocess International. 2021; 19(4):87-95
6. Gupta V, Kumar P, Shukla A. Transitioning from batch to continuous biopharmaceutical manufacturing: A critical evaluation. International Journal of Pharmaceutics. 2019; 567(1):156-62.
7. Anderson T, Zhang L, Gomez E. Comparative economic analysis of batch versus continuous manufacturing of biologics. Journal of Biotechnology and Pharmaceutical Sciences. 2021; 13(9):92-100.
8. Patel S, Chan C, Tiwari R. Hybrid biopharmaceutical manufacturing: Leveraging the best of both continuous and batch systems. Pharmaceutical Engineering Journal. 2020; 34(7):22-30.
9. Wu Z, Liu Q, He Y. Process optimization and quality control in hybrid biopharmaceutical production systems. In: Proceedings of the Biopharmaceutical Production Conference, 2020: 99-104.
10. Lee Y, Zhang X, Lee J. Advanced manufacturing systems for monoclonal antibodies: A comparative study of batch, hybrid, and continuous processes. Biotechnology Advances. 2019; 37(5):63-72.
11. Zhang H, Shi J, Huang L. Real-time monitoring and quality control in continuous and hybrid biopharmaceutical manufacturing. Journal of Pharmaceutical Technology. 2021; 25(8):202-9.
12. Jackson M, Wu L, Li M. A hybrid approach to biopharmaceutical manufacturing: Balancing flexibility and efficiency. Journal of Bioprocess Engineering. 2019; 18(6):233-40.
13. Roberts L, Zhao P, Lee C. Cost and throughput analysis of continuous versus hybrid systems in mAb production. Biopharmaceutical Engineering Review. 2021; 11(3):55-61.